Key result
Tailored antiplatelet therapy provides the optimal balance of ischemic and bleeding risks after PCI in elderly patients.
Why the study?
Elderly patients undergoing PCI face higher risks of both thrombotic events and bleeding complications, requiring careful decision-making to identify the most appropriate oral antiplatelet regimen.
What is the optimal oral antiplatelet therapy strategy for elderly patients undergoing percutaneous coronary intervention?
Systematic Review (n=313,460)
What is the optimal oral antiplatelet therapy strategy for elderly patients undergoing percutaneous coronary intervention?
Individualized antiplatelet therapy, typically dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, is paramount for elderly patients undergoing PCI to appropriately balance thrombotic and bleeding risks.
Supports individualized DAPT in elderly PCI to balance risks; reinforces consensus from 8 prior systematic reviews.
Percutaneous coronary intervention has become a mainstay in the management of coronary artery disease. While initially advanced age was considered a relative contraindication to invasive management of coronary artery disease, current cardiovascular practice stands solidly on an early invasive approach for elderly patients, typically based on radial access and drug-eluting stent implantation. Since the advent of coronary stents, oral antiplatelet therapy has proved crucial to maximize the benefits and minimize the risks of stenting, and this holds even truer in older patients rather than in younger ones. Indeed, the elderly is typically at higher risk of thrombotic events as well as bleeding complications, and thus careful decision making must be exercised to prescribe the most appropriate antiplatelet regimen. We thus conducted an umbrella review with scoping purposes on oral antiplatelet therapy in elderly patients undergoing percutaneous coronary intervention, retrieving 8 pertinent systematic reviews. We found that, while several drugs are available, ranging from aspirin to cilostazol, clopidogrel, dipyridamole, prasugrel, ticagrelor, and ticlopidine, most commonly a dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is recommended, with subtle adjustments for pretreatment, loading, dose, duration, escalation or de-escalation, with the potential adjunct in selected patients of novel oral anticoagulants. Indeed, a flexible and individualized approach to oral antiplatelet therapy in elderly patients undergoing percutaneous coronary intervention is paramount, factoring patient features (exploiting thrombotic, bleeding and frailty scores), triage (including when appropriate non-invasive assessment of anatomic and functional significance of coronary artery disease), angiographic and other invasive imaging features, interventional technique, stent choice, rehabilitation, and secondary prevention.
No takes yet. Share an insight, caveat, or question.
Biondi‐Zoccai et al. (2020) conducted a systematic review in Coronary artery disease undergoing percutaneous coronary intervention (n=313,460). Oral antiplatelet therapy was evaluated. A flexible and individualized approach to oral antiplatelet therapy, most commonly dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, is recommended in elderly patients undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: